Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis
- 4 December 2017
- journal article
- review article
- Published by Springer Nature in Intensive Care Medicine
- Vol. 44 (2) , 167-178
Abstract
Polymyxin B-immobilized hemoperfusion (PMX-HP) is an adjuvant therapy for sepsis or septic shock that clears circulating endotoxin. Prior trials have shown that PMX-HP improves surrogate endpoints. We aimed to conduct an evidence synthesis to evaluate the efficacy and safety of PMX-HP in critically ill adult patients with sepsis or septic shock.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP16J10320)
This publication has 47 references indexed in Scilit:
- Blood Purification and Mortality in SepsisCritical Care Medicine, 2013
- High-dose renal replacement therapy for acute kidney injury: Systematic review and meta-analysisCritical Care Medicine, 2010
- An evidence-based practice guideline for the peer review of electronic search strategiesJournal of Clinical Epidemiology, 2009
- Intensity of Renal Support in Critically Ill Patients with Acute Kidney InjuryNew England Journal of Medicine, 2008
- Polymyxin-B hemoperfusion inactivates circulating proapoptotic factorsIntensive Care Medicine, 2008
- Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic reviewCritical Care, 2007
- A PILOT-CONTROLLED STUDY OF A POLYMYXIN B-IMMOBILIZED HEMOPERFUSION CARTRIDGE IN PATIENTS WITH SEVERE SEPSIS SECONDARY TO INTRA-ABDOMINAL INFECTIONShock, 2005
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceIntensive Care Medicine, 2003
- The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failureIntensive Care Medicine, 1996
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986